GSK shutting down Biopolis neural unit
Other ongoing investments here not affected; UK pharma giant remains committed to R&D in Singapore
Add BT as a preferred sourceSingapore
IN a move to cut costs, United Kingdom pharma giant GlaxoSmithKline (GSK) will begin a phased closure of its operations at its neural pathways discovery performance unit at Biopolis, following its global review to refocus the global pharmaceuticals business.
While it declined to reveal the number of employees affected by the closure, the drugmaker, which employs 1,700 people here, said it remains committed to research and development (R&D) in Singapore, which is a "a key location for GSK's global manufacturing and commercial operations".
TRENDING NOW
Haidilao co-founder’s family buys second bungalow in Cluny Hill for S$85 million
Yeo’s, Tiger Beer and now Gardenia – flight of food manufacturing from Singapore might be just as planned
Prabowo’s biggest crackdown on tycoons shocked his own officials
Apex court rejects resulting trust claim in 99-1 condo dispute
